NASDAQ:GOSS Gossamer Bio (GOSS) Stock Price, News & Analysis $0.83 +0.00 (+0.02%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Gossamer Bio Stock (NASDAQ:GOSS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Gossamer Bio alerts:Sign Up Key Stats Today's Range$0.80▼$0.8750-Day Range$0.78▼$1.5352-Week Range$0.50▼$1.55Volume980,087 shsAverage Volume1.56 million shsMarket Capitalization$188.62 millionP/E RatioN/ADividend YieldN/APrice Target$7.75Consensus RatingBuy Company OverviewGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Read More… Remove Ads Gossamer Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreGOSS MarketRank™: Gossamer Bio scored higher than 76% of companies evaluated by MarketBeat, and ranked 226th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGossamer Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGossamer Bio has only been the subject of 2 research reports in the past 90 days.Read more about Gossamer Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gossamer Bio are expected to decrease in the coming year, from ($0.28) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gossamer Bio is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gossamer Bio is -2.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGossamer Bio has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Gossamer Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.70% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Gossamer Bio has recently increased by 38.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGossamer Bio does not currently pay a dividend.Dividend GrowthGossamer Bio does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.67 Percentage of Shares Shorted3.70% of the float of Gossamer Bio has been sold short.Short Interest Ratio / Days to CoverGossamer Bio has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Gossamer Bio has recently increased by 38.85%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.30 News SentimentGossamer Bio has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Gossamer Bio this week, compared to 2 articles on an average week.Search Interest11 people have searched for GOSS on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows2 people have added Gossamer Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gossamer Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.00% of the stock of Gossamer Bio is held by insiders.Percentage Held by Institutions81.23% of the stock of Gossamer Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gossamer Bio's insider trading history. Receive GOSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address GOSS Stock News HeadlinesIs Gossamer Bio Inc. (NASDAQ:GOSS) the Best Penny Stock to Invest in Under $1?April 16 at 11:28 PM | msn.comGossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will TripleApril 11, 2025 | msn.com[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.April 17, 2025 | Colonial Metals (Ad)phaware® Launches Special Series of Podcast Episodes Spotlighting the Future of PH-ILD Treatment and InnovationApril 1, 2025 | finance.yahoo.comIs Gossamer Bio, Inc. (GOSS) The Hot Biotech Stock Under $5?March 26, 2025 | insidermonkey.comGossamer Bio (GOSS): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.com10 Hot Biotech Stocks Under $5March 23, 2025 | insidermonkey.comGOSSAMER BIO Earnings Preview: Recent $GOSS Insider Trading, Hedge Fund Activity, and MoreMarch 21, 2025 | nasdaq.comSee More Headlines GOSS Stock Analysis - Frequently Asked Questions How have GOSS shares performed this year? Gossamer Bio's stock was trading at $0.9046 at the beginning of 2025. Since then, GOSS shares have decreased by 8.2% and is now trading at $0.8301. View the best growth stocks for 2025 here. How were Gossamer Bio's earnings last quarter? Gossamer Bio, Inc. (NASDAQ:GOSS) posted its earnings results on Tuesday, March, 18th. The company reported ($0.15) EPS for the quarter, meeting the consensus estimate of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analysts' expectations of $7.02 million. When did Gossamer Bio IPO? Gossamer Bio (GOSS) raised $230 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 14,400,000 shares at a price of $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI acted as the underwriters for the IPO. How do I buy shares of Gossamer Bio? Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gossamer Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gossamer Bio investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings3/18/2025Today4/16/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GOSS CIK1728117 Webwww.gossamerbio.com Phone(858) 684-1300FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$7.75 High Stock Price Target$10.00 Low Stock Price Target$4.00 Potential Upside/Downside+833.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-179,820,000.00 Net MarginsN/A Pretax Margin-64.89% Return on Equity-127.28% Return on Assets-22.12% Debt Debt-to-Equity Ratio3.64 Current Ratio6.74 Quick Ratio6.74 Sales & Book Value Annual Sales$114.70 million Price / Sales1.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book2.96Miscellaneous Outstanding Shares227,221,000Free Float215,274,000Market Cap$188.62 million OptionableOptionable Beta1.88 Free Today: Your Guide to Smarter Options TradesLearn how options trading can help you navigate market volatility, manage risk, and maximize returns with MarketBeat's "Unlock the Potential in Options Trading." Click the link below to have this special report delivered to your inbox.Get This Free Report This page (NASDAQ:GOSS) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.